@entity6 , @entity2449 and incidence of and @entity204 from XXXX in postmenopausal @entity1 : Results from the @entity1 's health initiative.

@entity1 @entity0 @entity6 @entity5 @entity3 @entity204 @entity2449
Findings from studies of @entity2449 use with risk of @entity5 incidence and outcome provide mixed results; with few studies examined associations by recency of @entity6 diagnosis or duration of medication use. Thus, in the @entity1 's Health Initiative, we examined these associations and further explored whether associations differ by recency of @entity6 and duration of @entity2449 use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. @entity6 was associated with higher risk of @entity3 (HR, 1.13; p   <   0.001) and of several site-specific @entity5 (HR, 1.2-1.4, and up to over twofold). @entity6 was also associated with higher risk of @entity204 from @entity5 (HR, 1.46; p   <   0.001). There was no overall difference in @entity5 incidence by @entity6 therapy (p   =   0.66). However, there was a lower risk of @entity204 from @entity5 for @entity2449 users, compared to users of other medications, relative to @entity1 without @entity6 , overall (HRs, 1.08 vs. 1.45; p   =   0.007) and for @entity0 (HRs, 0.50 vs. 1.29; p   =   0.05). Results also suggested that lower @entity5 risk associated with @entity2449 may be evident only for a longer duration of use in certain @entity5 sites or subgroup populations. We provide further evidence that postmenopausal @entity1 with @entity6 are at higher risk of @entity3 and @entity5 @entity204 . @entity2449 users, particularly long-term users, may be at lower risk of developing certain @entity5 and dying from @entity5 , compared to users of other anti- @entity6 medications. Future studies are needed to determine the long-term effect of @entity2449 in @entity5 risk and survival from @entity5 .
